Philip Morris' impressive Q3 results highlight robust performance in both core and reduced-risk products. Read why I remain ...

The recent decision by the US Food and Drug Administration (FDA) to authorise the marketing of 20 ZYN nicotine pouches has reignited the global conversation around harm reduction policies in tobacco ...